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Background
The nitric oxide (NO)-soluble guanylate cyclase (sGC)-
cyclic guanosine 3’5’-monophosphate (cGMP) pathway
regulates intraocular pressure (IOP). Preclinical and clin-
cial studies have demonstrated the ability of NO-donor
compounds to lower IOP (e.g. VESNEO®). The use of
inhaled NO gas (iNO), a specific pulmonary but not sys-
temic vasodilator, is an approved therapy for pulmonary
hypertension and is under development as a treatment
for other cardiovascular diseases (e.g. for myocardial
ischemia, the NOMI trial). We hypothesized that breath-
ing NO lowers IOP in an sGC-dependent manner.
Methods
Anesthetized IOP model: 10- to 20-week-old male wild-
type (WT) mice and mice deficient in the a1-subunit of
sGC (sGCa1-/- mice; n=9, each) were anesthetized with
isoflurane using a standard protocol resulting in a stable
IOP baseline. Ten minutes after baseline measurement,
IOP was measured again in mice breathing 1.8 % isoflur-
ane and either control gas (N2 balanced in O2) or 40 ppm
NO balanced in O2. Awake IOP model: WT mice were
acclimated to awake IOP measurements (every other day
for 2 weeks). 40 min after baseline measurements, IOP
was measured in mice breathing either control gas or
40 ppm iNO (n=8, each) in an incubation chamber.
Results
Breathing control gas did not affect IOP in WT or
sGCa1-/- mice (Figure 1). Breathing iNO decreased IOP
in both anesthetized WT mice (9.86±0.31 vs. 8.42±0.51
mmHg at baseline and after iNO, respectively, Figure 1a)
and awake WT mice (14.13±1.95 vs. 10.93±1.01 mmHg,
at baseline and after 40 min iNO, respectively, Figure 1b).
In contrast, iNO did not lower IOP in sGCa1-/- mice
(9.75±0.31 vs. 9.46±0.30 mmHg at baseline and after
iNO, respectively, Figure 1a).
Conclusion
Inhalation of 40 ppm iNO decreased IOP in anesthe-
tized and awake WT mice but not in sGCa1-/- mice.
These findings confirm that NO is an IOP-lowering
Figure 1 iNO decreases IOP in WT but not sGCa1-/- mice:
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agent, and identify NO-gas as a possible therapeutic
approach to acutely lower IOP. In addition, our results
identify sGC as the downstream target of NO’s ability to
lower IOP. sGC stimulators, under development for
treatment of cardiovascular diseases, such as the
recently approved ADEMPAS®, may be considered as a
novel treatment option for elevated IOP.
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